| Bioactivity | Adalimumab (Powder) is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α)[1][2]. |
| Invitro | 使用 Adalimumab 处理 HUVEC 长达 12 小时，显示对其细胞活力没有不利影响，即使 Adalimumab 的浓度比本研究中使用的浓度高 10 倍[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Adalimumab (Powder) 相关抗体: |
| In Vivo | Adalimumab 的消除半衰期很长 (t1/2=~20 天)[1]。 荧光标记的 Adalimumab 富集主要在油红 O 阳性病变中观察到，证明药物进入动脉粥样硬化斑块的良好组织渗透性，在溶剂对照注射到高胆固醇血症 Ldlr-/- 老鼠后，血管壁无背景荧光[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 331731-18-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ternant D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015 Feb;79(2):286-97. [2]. Oberoi R, et al. Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS One. 2016 Jul 28;11(7):e0160145. |